

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

**Kore Potash PLC (ASX: KP2)**

ARBN

**621 843 614**

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |  |  |
|--|--|
| <p>1 +Class of +securities issued or to be issued</p>  | <p>(i) Fully paid ordinary shares (AIM)<br/>           (ii) Equity warrants – exercisable at A\$0.30 each expiring on 29 March 2021<br/>           (iii) Performance Rights<br/>           (iv) Unlisted Options exercisable at £0.11 each expiring on 27 June 2020<br/>           (v) Unlisted Options exercisable at £0.11 each expiring on 27 June 2028</p> |
| <p>2 Number of +securities issued or to be issued (if known) or maximum number which may be issued</p> | <p>(i) 1,618,250 Fully paid ordinary shares (AIM)<br/>           (ii) 250,000 Equity warrants<br/>           (iii) 4,500,000 Performance Rights<br/>           (iv) 4,000,000 Unlisted Options<br/>           (v) 17,200,000 Unlisted Options</p>  |

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

- (i) Same terms as other fully paid ordinary shares
- (ii) Exercisable at A\$0.30 each expiring on 29 March 2021
- (iii) Unconditional vesting in three equal tranches on the first, second and third anniversary of the Company's admission to the AIM, expiry date of 22 May 2022.
- (iv) Exercisable at £0.11 each expiring on 27 June 2020
- (v) Exercisable at £0.11 each expiring on 27 June 2028

4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (i) Yes, same as other fully paid ordinary shares
- (ii) No, only when exercised to fully paid ordinary shares
- (iii) No, only when exercised to fully paid ordinary shares
- (iv) No, only when exercised to fully paid ordinary shares
- (v) No, only when exercised to fully paid ordinary shares

5 Issue price or consideration

- (i) Deemed price of A\$0.20 per fully paid ordinary share
- (ii) Included in (i) at a deemed price of one equity warrant for each US\$1.00 invested
- (iii) Nil (Replacement Performance Rights)
- (iv) Nil
- (v) Nil

---

+ See chapter 19 for defined terms.

<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<ul style="list-style-type: none"> <li>(i) Conversion of US\$250,000 convertible loan into fully paid ordinary shares following shareholder approval at the AGM held on 27 June 2018 (refer Resolution 14)</li> <li>(ii) Issue of equity warrants accompanying the convertible note under (i) at a deemed price of one equity warrant for each US\$1.00 invested.</li> <li>(iii) Cancellation of existing Performance Rights held by Directors and issue of new Performance Rights following shareholder approval at the AGM held on 27 June 2018 (refer Resolution 15 to 19)</li> <li>(iv) Issue of unlisted options following shareholder approval at the AGM held on 27 June 2018 (refer Resolution 20)</li> <li>(v) Issue of unlisted options following shareholder approval at the AGM held on 27 June 2018 (refer Resolution 21)</li> </ul>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>No</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>N/A</p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p>N/A</p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p>N/A</p>
<p>6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)</p>	<p>N/A</p>
<p>6f Number of +securities issued under an exception in rule 7.2</p>	<p>N/A</p>
<p>6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.</p>	<p>N/A</p>
<p>6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements</p>	<p>N/A</p>

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

N/A
-----

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

(i) 27 July 2018
(ii) 27 July 2018
(iii) 1 August 2018
(iv) 1 August 2018
(v) 1 August 2018

	Number	+Class
8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	431,112,811	Chess Depository Interests at a ratio of 1 CDI representing 1 fully paid ordinary share as issued on the ASX (noting that an additional 429,739,882 ordinary shares are quoted on either the AIM market of the London Stock Exchange or the Johannesburg Stock Exchange).

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	50,000,000	Unlisted Options exercisable at AUD 0.30 each expiring 15 Nov 2019
	1,886,996	Class C Performance Rights each expiring 16 September 2019 (Emp)
	2,255,000	Performance Rights expiring 6 December 2020 (Emp)
	5,881,250	Performance Rights expiring 1 March 2021 (Dir)
	660,000	Performance Rights vesting on 31 May 2019 (Dir)
	1,405,000	Performance Shares vesting on 31 May 2019
	3,747,005	Performance Shares under a Short Term Incentive Scheme Plan for 2017
	11,734,853	Performance Shares under the Long Term Incentive Plan
	13,144,659	Equity Warrants exercisable at A\$0.30 each expiring 29 March 2021
	4,500,000	Performance Rights expiring 22 May 2022 (Dir)
	4,000,000	Unlisted Options exercisable at £0.11 each expiring on 27 June 2020

+ See chapter 19 for defined terms.

17,200,000	Unlisted Options exercisable at £0.11 each expiring on 27 June 2028
------------	---

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
----	--	-----

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
----	---------------------------------------	-----

12	Is the issue renounceable or non-renounceable?	N/A
----	--	-----

13	Ratio in which the +securities will be offered	N/A
----	--	-----

14	+Class of +securities to which the offer relates	N/A
----	--	-----

15	+Record date to determine entitlements	N/A
----	--	-----

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
----	--	-----

17	Policy for deciding entitlements in relation to fractions	N/A
----	---	-----

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
----	--	-----

19	Closing date for receipt of acceptances or renunciations	N/A
----	--	-----

20	Names of any underwriters	N/A
----	---------------------------	-----

21	Amount of any underwriting fee or commission	N/A
----	--	-----

22	Names of any brokers to the issue	N/A
----	-----------------------------------	-----

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	+Issue date	N/A

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities  
(tick one)
- (a)  +Securities described in Part 1

---

+ See chapter 19 for defined terms.

(b)  All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
- 1 - 1,000
  - 1,001 - 5,000
  - 5,001 - 10,000
  - 10,001 - 100,000
  - 100,001 and over
- 37  A copy of any trust deed for the additional +securities

### Entities that have ticked box 34(b)

- 38 Number of +securities for which +quotation is sought
- 39 Class of +securities for which quotation is sought
- 40 Do the +securities rank equally in all respects from the +issue with an existing +class of quoted +securities?
- If the additional +securities do not rank equally, please state:
- the date from which they do
  - the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
  - the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
-

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

--

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class

**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
 Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We

---

+ See chapter 19 for defined terms.

acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

[ signed electronically ]

Sign here: .....Date: 2 August 2018  
Joint Company Secretary

Print name: Henko Vos

== == == == ==